Pharvaris NV
PHVS
Ver gráfico detallado
26.420USD
+1.280+5.09%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
1.72BCap. mercado
PérdidaP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Hoy
+5.09%
5 Días
-2.33%
1 Mes
+9.85%
6 Meses
+24.45%
Año hasta la fecha
-4.79%
Un año
+44.69%
Ver gráfico detallado
Puntuación de acciones TradingKey
No hay puntuación de la acción disponible debido a la falta de datos.
Pharvaris NV Noticias
Próximamente más noticias, permanezca atento...
Indicadores financieros
BPA
La empresa aún no ha revelado los datos relevantes.
Ingresos totales
La empresa aún no ha revelado los datos relevantes.
Información de Pharvaris NV
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Símbolo de cotizaciónPHVS
CompañíaPharvaris NV
Director ejecutivoModig (Berndt B.A.E)
Sitio Webhttps://pharvaris.com/
Instrumentos Relacionados
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Símbolos Populares
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68951.090
-1019.040 (-1.46%)
282.580
+22.390 (+8.61%)
2034.300
-17.430 (-0.85%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
